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ARTICLE
Deﬁning the Cause of Skewed X-Chromosome Inactivation
in X-Linked Mental Retardation by Use of a Mouse Model
Mary R. Muers, Jacqueline A. Sharpe, David Garrick, Jacqueline Sloane-Stanley, Patrick M. Nolan,
Terry Hacker, William G. Wood, Douglas R. Higgs, and Richard J. Gibbons
Extreme skewing of X-chromosome inactivation (XCI) is rare in the normal female population but is observed frequently
in carriers of some X-linked mutations. Recently, it has been shown that various forms of X-linked mental retardation
(XLMR) have a strong association with skewed XCI in female carriers, but the mechanisms underlying this skewing are
unknown. ATR-X syndrome, caused by mutations in a ubiquitously expressed, chromatin-associated protein, provides a
clear example of XLMR in which phenotypically normal female carriers virtually all have highly skewed XCI biased
against the X chromosome that harbors the mutant allele. Here, we have used a mouse model to understand the processes
causing skewed XCI. In female mice heterozygous for a null Atrx allele, we found that XCI is balanced early in embry-
ogenesis but becomes skewed over the course of development, because of selection favoring cells expressing the wild-
type Atrx allele. Unexpectedly, selection does not appear to be the result of general cellular-viability defects in Atrx-
deﬁcient cells, since it is restricted to speciﬁc stages of development and is not ongoing throughout the life of the animal.
Instead, there is evidence that selection results from independent tissue-speciﬁc effects. This illustrates an important
mechanism by which skewed XCI may occur in carriers of XLMR and provides insight into the normal role of ATRX in
regulating cell fate.
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X-chromosome inactivation (XCI) is the mechanism by
which gene dosage equivalence is achieved between fe-
male (XX) and male (XY) mammals.1 XCI occurs in in-
dividual cells early in embryonic development and is
subsequently stably maintained in all daughter cells.
Therefore, each tissue of an adult female is composed of
cells that express either the maternal or the paternal X
chromosome. Because which X chromosome will be si-
lenced is random, in the general female population, XCI
ratios have a normal distribution, with an average of ∼50:
50, so that an equal number of cells express the maternal
and paternal chromosomes.2 Therefore, by chance, a small
percentage of females (∼9%) have a skewed ratio (180:20),
where there is a bias toward cells expressing one or the
other X chromosome, but extreme skewing (195:5) is very
rare (in !1% of females).2
Whereas skewed XCI is rare in the normal population,
it is relatively common in carriers of X-linked mutations
and in cases of X-autosome translocations. In principle,
heterozygosity for an X-linked mutation could cause
skewed XCI, either by biasing the primary pattern of XCI
(as is the case for the Xce locus in mice3–6) or through
secondary selection in favor of cells expressing a particular
X chromosome.7–9 When skewed XCI is limited to speciﬁc
tissues,10,11 it can be assumed that this is because of cell
selection, but, when XCI is skewed to a similar extent in
many or all tissues, although this could result from cell
selection due to a defect in a basic cellular function, this
is not necessarily the case.
Recently, it has been shown that severalX-linkedmental
retardation (XLMR) disorders have a strong association
with skewed XCI in carrier females.12 However, the mech-
anism underlying skewing in these cases is unknown. A
clear example of this association is seen in the a-thalas-
semia XLMR syndrome (ATR-X syndrome [MIM 301040]).
Affected males have profound psychomotor retardation
and multiple congenital abnormalities, including facial
dysmorphism and urogenital and skeletal defects.13–15ATR-
X syndrome was originally identiﬁed via the unusual as-
sociation of mental retardation with mild a-thalassemia,
characterized by the formation of HbH inclusions (b-glo-
bin tetramers) in red blood cells.16 ATRX is a ubiquitously
expressed, chromatin-associated protein of the Snf2 family
and is thought to affect the expression of a-globin and a
wide range of other genes via epigenetic mechanisms.17–22
Nearly all female carriers of ATR-X syndrome have
highly skewed XCI in favor of cells expressing the normal
ATRX allele and are essentially phenotypically normal.23
In some carriers, a few red cells (∼1% of the frequency
seen in affected males) contain HbH inclusions. In a
unique carrier female with balanced XCI in the peripheral
blood, the percentage of HbH cells (0.9%) was similar to
that seen in affected males, consistent with skewed XCI
being the mechanism by which such carriers are normally
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protected from the deleterious effects of an ATRX
mutation.23
Like ATRX, many XLMR genes are widely expressed and
are predicted to regulate general nuclear processes, such
as transcription, DNA repair, and cell proliferation.24
Therefore, it has been proposed that mutations in such
genes should result in general defects inﬂuencing cell vi-
ability or proliferation and thus should result in skewed
XCI (due to cell selection) in a wide variety of cell types.12
Although most analyses of XCI in XLMR have been per-
formed on peripheral blood, in ATR-X syndrome, skewed
XCI has been demonstrated in buccal cells, hair roots, and
peripheral blood (originating from endoderm, ectoderm,
and mesoderm, respectively). As originally proposed,23
this could result from cell selection prior to the differ-
entiation of the embryo into separate tissue types, from
separate selection events in different tissues, or from an
effect of the mutation on the primary establishment of
XCI. Which of these actually occurs in vivo has not yet
been demonstrated for any form of XLMR in which carrier
females have skewed XCI.
Here, we have examined the pattern of XCI in female
mice heterozygous for a null mutation in the highly con-
served mouse orthologue of ATRX (Atrx [GenBank acces-
sion number NM_009530]).25,26 The carrier femalemice are
viable and fertile, unlike males hemizygous for this mu-
tation,25 and they therefore provide a model in which XCI
can be assessed in a range of tissues throughout devel-
opment. We have shown that skewed XCI results from
selection against Atrx-deﬁcient cells at speciﬁc stages of
development and differentiation in different tissues. These
ﬁndings illustrate an important mechanism by which
skewed XCI may occur in carriers of XLMR and provide
insight into the normal role of ATRX in vivo.
Material and Methods
Atrx Mice
Atrx-mutant mice were generated, as described by Garrick et al.,25
by homologous recombination in embryonic stem cells (E14, de-
rived from 129/OlaHsd) and by injection of C57BL/6 blastocysts
with the targeted cells. All wild-type mice used were F1 CBA/
C57BL/6. Atrxwt/null females were obtained by crossing animals
with a ﬂoxed Atrx allele and transgenic animals with Cre recom-
binase expressed from the Gata1 promoter.25,27 The Atrxwt/null em-
bryos used were from crosses between these Atrxwt/null females and
wild-type males. Mice with the ﬂoxed Atrx allele were also crossed
with animals with a Cre recombinase transgene under the control
of an inducible Mx1 promoter (Mx1Cre).28 Adult mice were ge-
notyped at the Atrx locus by hybridizing SacI-digested DNA on
Southern blots with an intron 17 probe, and embryos were ge-
notyped by PCR with primers PPS1.17 (intron 17) and PPS1.28
(exon 19) (both methods described by Garrick et al.25). The
Mx1Cre transgene was detected by PCR (forward primer 5′-GCG-
GAGCCAGCACTATTTA-3′; reverse primer 5′-CCGGCATCAACG-
TTTTCTTTT-3′).29
Animal Husbandry
To obtain staged embryos, the morning on which a vaginal plug
was noted was taken as embryonic day (E) 0.5. Mice were sacri-
ﬁced by cervical dislocation. To obtain blood from E9.5 and E10.5
embryos, pregnant females were given an intraperitoneal heparin
injection 5–10 min before they were sacriﬁced. Embryos were
separated from the uterine wall and placenta, then were released
from the yolk sac into a small volume of PBS/heparin, and were
allowed to bleed out. Cre recombination was induced in mice
with the ﬂoxed Atrx allele and Mx1Cre transgene by two intra-
peritoneal injections of 250 mg of the synthetic double-stranded
RNA polyinosinic-polycytidylic acid (pI-pC) 2 d apart, within 3
wk after birth. Tissue analysis was performed at least 6 wk after
pI-pC treatment, and the efﬁciency of recombination in hema-
topoietic samples was assessed by Southern blot after SacI diges-
tion (see above). Phenylhydrazine treatment to induce hemolytic
anemia consisted of three intraperitoneal injections of 0.04 mg
1-acetyl-2-phenylhydrazine (Sigma) per g of body weight at 17.00
on day 1 and at 09.00 and 17.00 on day 2.30 Mice were sacriﬁced
on day 6.
Immunohistochemistry, Immunoﬂuorescence, and FACS
Staged embryos and adult mouse tissues were ﬁxed in 4% para-
formaldehyde overnight at 4C. After a washing in PBS, samples
were dehydrated through an ethanol series and xylene and were
embedded in parafﬁn. Before the staining, 5-mm sections were
treated with Histo-Clear (Fisher Scientiﬁc) and were rehydrated.
When required, antigen unmasking was performed by heat treat-
ment in Antigen Unmasking Solution (Vector Laboratories). Sec-
tions were stained for immunohistochemistry by use of the Rabbit
ABC Staining System (Santa Cruz Biotechnologies), in accordance
with the manufacturer’s protocol, after endogenous peroxidase
activity was blocked with 3% H2O2. The antibodies used were
rabbit polyclonal anti-ATRX H300 (Santa Cruz Biotechnologies)
and normal rabbit immunoglobulin G (IgG) (Santa Cruz Bio-
technologies). Cells in suspension from peripheral blood, bone
marrow, fetal liver, and methylcellulose colonies were allowed to
settle onto poly-L-lysine–coated coverslips, were ﬁxed in 4% par-
aformaldehyde for 1 h at 4C, and were permeabilized with 0.5%
Triton-X 100 (in PBS) prior to incubation with antibodies. For
ﬂuorescence microscopy, the secondary antibodies used were Al-
exa 488–conjugated anti-rabbit IgG (Molecular Probes), ﬂuores-
cein isothiocyanate (FITC)–conjugated anti-rabbit IgG (Jackson
Laboratories), and Cy3-conjugated anti-rabbit IgG (Jackson Lab-
oratories), and slides were mounted in Vectashield with 4′,6-di-
amidino-2-phenylindole (DAPI) (Vector Laboratories). To isolate
erythroid cell populations by ﬂuorescence-assisted cell sorting
(FACS), single cell suspensions were incubated with a phycoer-
ythrin (PE)–conjugated anti-TER119 antibody (BD Pharmingen)
and an FITC-conjugated anti-CD71 antibody (BD Pharmingen).
Gated erythroblast populations were as described by Zhang et
al.31 Brieﬂy, early precursors were taken as CD71 medium/high,
Ter199 low; intermediate precursors were CD71 high, Ter119me-
dium; and intermediate/late precursors wereCD71medium/high,
Ter119 high.
Microscopy and Imaging
Light and ﬂuorescencemicroscopywas performedusingOlympus
BX61microscopes. Images were collected usingOpenLab software
for light microscopy and MacProbe 4.3 for ﬂuorescence micros-
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Figure 1. XCI in adult Atrxwt/null mice. Parafﬁn sections of tissues
from wild-type (WT) and Atrxwt/null female mice, stained with the
anti-Atrx antibody (H300) detected by horseradish peroxidase
(brown) with hematoxylin counterstain (blue). Sections stained
under the same conditions with an IgG control antibody gave a
weak background signal, as shown by Garrick et al.25 Red arrow-
heads indicate examples of Atrx-negative cells. The mean per-
centage (1 SD) of Atrx-negative cells in the cerebral cortex and
the granular layer of the cerebellum and the percentage of Atrx-
negative intestinal crypts is given (three animals, with 12,000
cells or crypts per genotype). Scale bars are 25 mm (A), 10 mm
(B), and 50 mm (C).
copy. Further image annotation was performed using Adobe Pho-
toshop 7.0.
Atrx Methylation
DNA from 11 Atrxwt/null (15 samples) and 4 Atrxwt/ﬂox (6 samples)
adult mice was digested with PstI and the methylation-sensitive
enzyme SacII and was analyzed by Southern blot. The probe used
to detect fragments, including the Atrx CpG island (5′ probe), was
generated by PCR (forward primer 5′-TTGCCTAACATGCACAA-
AGC-3′; reverse primer 5′-ATTGGCTACGGAAATTCACC-3′). The
relative intensity of bands resulting from methylated and un-
methylated fragments was determined using a Typhoon Phos-
phoImager (Amersham Biosciences) and ImageQuant software.
Hematopoietic Progenitor Colony Culture
Hematopoietic colony-forming assays by use of E13.5 fetal liver
and adult bone marrow were performed using MethoCult Media
(Stem Cell Technologies 03434) in accordance with the manu-
facturer’s guidelines. Colony type was determined by cell mor-
phology, as described by Stem Cell Technologies. Colonies were
picked after 7 d of culture or after 14 d for mixed-lineage colonies.
Results
Skewed XCI in Adult Atrxwt/null Mice
The targeted Atrx allele (Atrxﬂox), described previously by
Garrick et al.,25 enables conditional knockout of the full-
length isoform of Atrx by Cre-mediated recombination.
Male cells hemizygous for the recombined null allele
(Atrxnull) or female heterozygous cells (Atrxwt/null) with the
null allele on the active X chromosome lack expression
of full-length Atrx. They can be distinguished from wild-
type cells or heterozygous cells with the wild-type allele
on the active X chromosome by staining with an antibody
speciﬁc for full-length Atrx (H300).25,32 Although female
Atrxwt/null mice are viable and fertile, some do exhibit mild
behavioral abnormalities, including increased aggression
and hyperactivity (J.A.S., unpublished data). Preliminary
data from behavioral studies showed that a proportion of
heterozygotes performed poorly in a T-maze test, sug-
gesting impaired learning and/or memory (P.M.N., un-
published data).
We initially assessed the XCI pattern in adult Atrxwt/null
females, by immunohistochemical analysis for Atrx ex-
pression, to determine whether skewed XCI is present in
mice as it is in humans. Tissues were chosen for analysis
in which the majority of cells (90%–100%) expressed Atrx
in wild-type samples (ﬁg. 1). If XCI were balanced, in
Atrxwt/null females, one would expect ∼50% of the cells to
lack Atrx expression due to the null allele being on the
active X chromosome. In heterozygotes, the percentage
of cells lacking Atrx expression was higher than in wild-
type cells but remained !20% in the cerebral cortex and
the granular layer of the cerebellum, as well as in the
crypts of Lieberkuhn and epithelia of intestinal villi (ﬁg.
1). Villi develop as clonal populations of cells, so each is
either Atrx positive or Atrx negative. In a range of other
tissues, including kidney, ovary, and muscle, a similar bias
in favor of cells expressing Atrx was observed in hetero-
zygous samples (data not shown). The observation of
!20% Atrx-negative cells in adult tissues indicates that
Atrxwt/null mice do have skewed XCI in favor of cells with
the wild-type allele on the active chromosome, similar to
the situation in human female carriers of ATR-X syn-
drome. This analysis shows that this is a suitable model
to examine the causes of skewed XCI and conﬁrms that
XCI is skewed in tissues that are inaccessible in humans.
No Effect of Atrx Mutation on Primary Pattern of XCI or
Early Cell Selection
To determine whether skewed XCI in ATR-X carrier fe-
males is likely to be because of an effect of ATRXmutation
on the primary pattern of XCI or secondary selection
events during development, we assessed the XCI pattern
in E8 embryos. At E8, Atrxwt/null embryos are mosaics of
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Figure 2. Pattern of XCI during embryonic development. A, Parafﬁn sections of ∼E8 wild-type (WT) and Atrxwt/null littermate embryos,
stained with the anti-Atrx antibody (H300) and hematoxylin counterstain (as in ﬁg. 1). Examples of Atrx-positive and -negative cells
are indicated in panel iii. The mean percentage Atrx-negative cells (1 SD) was calculated from three Atrxwt/null embryos (12,000 cells
were scored in total). The punctate nuclear staining observed at higher magniﬁcation (iii) is typical for Atrx localization at heterochromatic
foci. Scale bars are 100 mm (i and ii) and 25 mm (iii). B, Percentage of cells negative for Atrx at E9.5, E12.5, E14.5, and E17.5, scored
by staining the tissue sections as in panel A. Each bar is the mean of percentages from a number of embryos (n); error bars are 1
SD. The number of cells scored per tissue per embryo is 100–1,000 at E9.5 and 500–2,500 at other stages. The horizontal dashed line
indicates the mean of the values from all the tissues shown at each time point and is an estimate of the overall percentage of Atrx-
negative cells. C p the postmitotic zone of the developing brain cortex; DRG p dorsal root ganglia; V p proliferative ventricular
zone. C, Examples of Atrxwt/null tissues at E14.5, stained as in panel A, with the percentage of Atrx-negative cells shown. Scale bars are
50 mm (i and ii) and 25 mm (iii and iv).
Atrx-expressing and -nonexpressing cells (ﬁg. 2A), with
Atrx-negative cells present in all three primary germ layers
(endoderm, ectoderm, and mesoderm) at ∼40% of the to-
tal cell number.
Because Atrx-negative cells were found throughout the
embryo, it seems that there is no strong selection against
these cells during the establishment of XCI or in the des-
ignation of the germ layers. The reduced percentage of
negative cells (∼40%) could be explained either by a weak
competitive disadvantage of the null cells or by a bias in
the original XCI ratio due to heterozygosity at the Xce
locus, which can cause a bias in the choice of XCI.3–6 How-
ever, the skewed XCI observed in adults must result from
secondary selection events that occur later in embryonic
development.
Skewed XCI Due to Cell Selection during Tissue Formation
We performed a systematic, detailed analysis of the XCI
pattern in a range of tissues at different stages of devel-
opment. Atrx can be detected in virtually all cells of wild-
type embryos throughout gestation (ﬁg. 3), but skewed
XCI (ratio 180:20) was apparent in most tissues by late
gestation (E17.5) in Atrxwt/null mice (ﬁg. 2B). However, al-
though the overall impression for the embryo as a whole
is of a gradual decline in Atrx-null cells during develop-
ment, at the level of individual tissues, the degree of cell
selection varied signiﬁcantly. For example, at E14.5 (ﬁg.
2B and 2C), the percentage of negative cells remained
30%–40% in the forebrain and dermis (mesenchyme) but
had declined to !20% in the epidermis and dorsal root
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Figure 3. Widespread expression of Atrx during embryonic development. Representative parafﬁn sections of wild-type mouse embryos
at the stages indicated were stained with an anti-Atrx antibody (H300, with HRP detection). At higher magniﬁcation (of E14.5 primitive
glomerulus), punctate nuclear localization at heterochromatic loci is observed. The level of Atrx protein is not uniform in all tissues—
for example, there is stronger staining in the postmitotic preplate than in the proliferative ventricular zone of the developing brain.
Scale bars are 10 mm for the primitive glomerulus and 100 mm for all other images.
ganglia. These data indicate that skewed XCI is a result of
secondary cell selection but, interestingly, suggest that the
selection pressure varies between cell lineages.
Stability of XCI Status
We next considered the possibility of whether the high
proportion of Atrx-positive cells could alternatively be ex-
plained by reactivation of the silent wild-type allele.Many
gene promoters on the inactive X chromosome are char-
acterized by methylated CpG islands, whereas these loci
are unmethylated on the active X. Therefore, females nor-
mally have an ∼50:50 ratio of methylated:unmethylated
X-chromosome CpG island alleles. Reactivation of the si-
lent allele would be expected to result in loss of methyl-
ation of that allele, detectable by a deviation from the
∼50:50 methylation ratio. We assessed the ratio of
methylated:unmethylated Atrx alleles in Atrxwt/null mice
and females without Cre recombination (Atrxwt/ﬂox), using
a methylation-sensitive restriction digest (ﬁg. 4), and
found an ∼50:50 ratio overall in both genotypes. Al-
though CpG island methylation is an indirect assay for
gene silencing, this suggested that the XCI status of
Atrxwt/null cells is stable. This conclusion is also supported
by the observation that, within the clonal cell populations
of intestinal villi, all cells are either Atrx negative or Atrx
positive (ﬁg. 1), which would be unlikely if spontaneous
reactivation of the silent allele occurred. Therefore, we can
be conﬁdent that cell selection is the mechanism that re-
sults in the increase in the proportion of Atrx-expressing
cells.
XCI in Hematopoiesis
Having determined that cell selection underlies skewed
XCI in carriers of an Atrx mutation, we next addressed the
question of whether selection is continual (i.e., due to a
general cellular defect affecting viability or proliferation,
as has been proposed for XLMR mutations) or limited to
particular stages of differentiation or development.
We initially analyzed skewing in the hematopoietic sys-
tem, because blood lineages are highly skewed in carriers
of ATR-X syndrome mutations.23 Embryonic hematopoi-
esis is divided into two phases, both of which were ana-
lyzed: the transient production of erythroblasts in the yolk
sac (“primitive” erythropoiesis), followed by the emer-
gence of hematopoietic stem cells (HSCs) and establish-
ment of “deﬁnitive” erythropoiesis in the fetal liver and
subsequently the bone marrow.
Primitive erythrocytes emerge from yolk sac mesoderm
at E7.5–E9 and continue to divide and differentiate in a
semisynchronous manner in circulation after release from
the blood islands.33–35 The pattern of XCI at three sequen-
tial stages of primitive erythroblast maturation was de-
termined by scoring the proportion of Atrx-negative er-
ythroid cells in yolk sac blood islands at E8 and in
circulation at E9.5 and E10.5 (ﬁg. 5). The percentage of
negative cells remained constant at ∼30% over this time
period, indicating that there is no continuing selection as
primitive erythroblasts undergo maturation and prolifer-
ation. However, the percentage of Atrx-negative erythro-
blasts (∼30%) was lower than the percentage in the em-
bryo overall at E8 (∼40%), suggesting that a lack of Atrx
may slightly reduce the probability of a cell participating
in blood island formation.
Differentiation of deﬁnitive erythroid cells from HSCs
can be broadly divided into the speciﬁcation of the ery-
throid program in multipotent progenitor cells, followed
by the differentiation and maturation of committed ery-
throid precursors (ﬁg. 6A).36 This process is established in
the fetal liver in midgestation mouse embryos and con-
tinues in the bone marrow throughout adult life. We iso-
lated cells at early, intermediate, and late stages of mat-
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Figure 4. Methylation of the Atrx promoter. A, Schematic representation of the 5′ end of Atrx, showing the position of the CpG island
and direction of transcription. The size of fragments generated by digesting genomic DNA with the restriction enzyme PstI alone (P)
or with both PstI and the methylation-sensitive enzyme SacII (S) is indicated. B, Southern-blot analysis (with use of the 5′ probe
shown in panel A) of DNA from adult female Atrxwt/ﬂox and Atrxwt/null mice after digestion with the two enzymes. Mp fragment obtained
from alleles with a methylated CpG island; U p fragment obtained from unmethylated copies of this sequence that are cut by both
PstI and SacII. C, Ratio of M:U calculated for each sample (shown as percentage of the total signal). Each group of points is from a
separate Southern blot and includes a range of tissue types (including brain, intestine, tail, ovary, and kidney). The example shown
in panel B is from tail DNA samples.
uration from E14.5 Atrxwt/null fetal livers by FACS. Almost
identically high proportions of Atrx-positive cells were ob-
served at all stages of maturation in both genotypes (ﬁg.
6B). The lack of Atrx-negative cells in Atrxwt/null samples
showed that XCI was almost completely skewed, indicat-
ing strong selection against cells lacking Atrx at an earlier
stage in erythropoiesis.
To study cells from earlier stages in differentiation, he-
matopoietic progenitor colonies were grown in methyl-
cellulose medium from Atrxwt/null and wild-type E13.5 fetal
liver and adult bone marrow, and Atrx expression in the
clonogenic colonies was assayed by immunoﬂuorescence.
Virtually no Atrx-negative colonies were found, irrespec-
tive of whether the colonies were from committed ery-
throid, myeloid, or multilineage progenitors (ﬁg. 6C).
Therefore, the XCI ratio is highly skewed at both the pro-
genitor and precursor stages of deﬁnitive erythropoiesis,
so cell selection must occur during the very earliest steps
in development of the hematopoietic system. These ob-
servations suggest that skewed XCI in adult blood lineages
is likely to be because of events during embryogenesis,
rather than selection during continual renewal of blood
cells.
Therefore, we were interested to determine when selec-
tion occurred during formation of HSCs. A major site of
emergence of deﬁnitive HSCs is the ventral wall of the
dorsal aorta in the aorta-gonads-mesonephros region of
the embryo at ∼E10.5. Intra-aortic clusters of cells have
been demonstrated to contain cells with HSC activity37–39
and can be observed by sectioning the embryos at this
stage of development. All cells in intra-aortic clusters ex-
press Atrx in wild-type embryos (data not shown), but,
although both positive and negative cells were observed
in Atrxwt/null embryos (ﬁg. 6D), the percentage of Atrx-neg-
ative cells in the clusters was only ∼15% (ﬁg. 6E). This
suggests a stronger selective pressure at the earliest stage
of deﬁnitive hematopoiesis, compared with primitive he-
matopoiesis (∼30% Atrx-negative cells). The observation
of cell selection in intra-aortic clusters, in conjunction
with the almost complete absence of Atrx-negative cells
at all stages of deﬁnitive erythropoiesis, strongly suggest
that selection during the establishment of the stem cell
population in the embryo results in highly skewed XCI
in adult blood.
Restricted Rather Than Continuous Cell Selection
To address whether selection is restricted or continuous
in deﬁnitive erythropoiesis, we circumvented selection
against Atrx-deﬁcient cells during embryonic develop-
ment by using an inducible Cre recombinase in postnatal
mice. Recombination between Lox P sites can be induced
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Figure 5. XCI in primitive erythropoiesis. Primitive erythroblasts in yolk sac blood islands at E8 (A) and in circulation at E9.5 and
E10.5 (B). A, Parafﬁn sections through the yolk sac of littermate wild-type (WT) and Atrxwt/null E8 embryos stained with an anti-Atrx
antibody (with hematoxylin counterstain). The red arrowhead indicates an example of an Atrx-negative erythroblast. Scale bars are 25
mm. B, Representative example of a pair of erythroid cells from Atrxwt/null E9.5 blood, stained for Atrx (green) and DAPI (blue). One
nucleus is Atrx positive, and the other is Atrx negative. All wild-type cells were Atrx positive. Both cells show some cytoplasmic
background. C, Percentage of Atrx-negative cells within embryonic tissues at E8 (E8 Emb) (see also ﬁg. 2) and primitive erythroblasts
in blood islands at E8 (E8 BI) and in circulation at E9.5 and E10.5. Approximately 750 cells in blood islands were scored from three
embryos, and ∼500 peripheral blood cells were scored at E9.5 (three embryos) and E10.5 (six embryos). Error bars are 1 SD.
in mice with a Cre recombinase transgene under the con-
trol of the inducible Mx1 promoter, by injection with in-
terferon or the double-stranded RNA pI-pC.28 We crossed
mice with the ﬂoxed Atrx allele toMx1Cre transgenicmice
and injected female Atrxwt/ﬂox and male Atrxﬂox pups with
pI-pC. Recombination using thismethod is not ubiquitous
but has been reported to be efﬁcient in the hematopoietic
system,28,40 and we conﬁrmed this by Southern-blot anal-
ysis of bone marrow and spleen samples (ﬁg. 7A). At least
6 wk after pI-pC treatment, the percentage of Atrx-nega-
tive cells in the bone marrow of female heterozygousmice
was ∼20%–35% (ﬁg. 8A).
Although there is continual turnover of hematopoietic
cells, we determined whether increased proliferation
would result in increased cell selection by inducing stress
erythropoiesis by phenylhydrazine treatment. Because
phenylhydrazine causes hemolytic anemia, it triggers
rapid proliferation of erythroid cells in the bone marrow
and spleen.30 However, this pressure on erythropoiesis did
not alter the proportion of Atrx-negative cells in hetero-
zygous female mice (ﬁg. 8B). Therefore, XCI does not be-
come severely skewed in adult erythropoiesis, irrespective
of the rate of cell division. In addition, a hematopoietic
progenitor colony assay with the use of bonemarrow from
a pI-pC treated female Atrxwt/ﬂox Mx1Cre mouse resulted
in an ∼50:50 ratio of positive:negative colonies, indicative
of balanced XCI (ﬁg. 8B). Also, male Atrxﬂox/Y Mx1Cre
mice, inwhich recombination to Atrxnull was inducedpost-
natally, were also viable and apparently able to pro-
duce normal blood in the absence of Atrx (ﬁgs. 7B and
8A), suggesting that Atrx is not essential for adult
erythropoiesis.
These results from whole bone marrow and bone mar-
row progenitor colonies after postnatal ablation of Atrx,
showing a signiﬁcant proportion of Atrx-negative cells,
contrast dramatically with the almost complete lack of
Atrx-negative cells at all stages of deﬁnitive erythropoiesis
in mice with an inherited Atrx mutation and to the highly
skewed XCI in female carriers of ATR-X syndrome. This
suggests that, although Atrx is important during embry-
onic development of the hematopoietic system, there is
nomajor requirement for Atrx during adult hematopoiesis
in the bone marrow. This means that, in the speciﬁc case
of hematopoiesis, cell selection is not a continuous
process.
To test the generality of this conclusion, we compared
the proportion of Atrx-negative cells in tissue sections
from pI-pC–treated Atrxﬂox/Y Mx1Cre males (to assess the
efﬁciency of Mx1Cre-mediated recombination), pI-pC–
treated Atrxwt/ﬂox Mx1Cre females, and Atrxwt/null females
with an inherited null allele (ﬁg. 8C). In both the crypts/
villi of the intestine and the glomerular cells of the kidney,
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Figure 6. Highly skewed XCI in deﬁnitive erythropoiesis. A, Schematic representation of the deﬁnitive erythropoietic lineage. Differ-
entiation of HSCs proceeds through a series of progenitor and precursor cells. CFU-GEMMp colony-forming unit–granulocyte/erythroid/
macrophage/megakaryocyte; BFU-E p burst forming unit–erythroid; CFU-E p colony-forming unit–erythroid. B and C, Cells at early
(E), intermediate (I), and late (L) stages of erythroid differentiation (see panel A) were isolated by FACS (sorted with antibodies against
CD71 and Ter119) from E14.5 wild-type and Atrxwt/null fetal livers. B, Example of intermediate stage cells stained with H300 antibody
and DAPI. The FITC-conjugated CD71 antibody used in FACS is also visible by immunoﬂuorescence. Atrx is typically observed at
concentrated nuclear foci in intermediate and late cells and in a punctate nuclear pattern in early erythroid cells. In panel C, cells in
each population were scored as Atrx negative, Atrx positive, or ambiguous/unclear staining (denoted by ?), shown as a percentage of
the total number of cells analyzed. Scores are pooled from two wild-type (WT) and two Atrxwt/null embryos (total of ∼350 Atrxwt/null cells).
Bone marrow (BM) from an Atrxwt/null adult and fetal liver (FL) from three E13.5 Atrxwt/null embryos were cultured in methylcellulose-
based medium to obtain hematopoietic progenitor colonies, which were then stained and scored for Atrx expression. Colony type was
determined by cell morphology and included granulocyte/macrophage colonies, erythroid and erythroid/megakaryocyte colonies, mac-
rophage colonies, and mixed colonies containing cells from multiple lineages. The few Atrx-negative colonies were not restricted to a
particular lineage. D and E, Intra-aortic clusters in Atrxwt/null embryos. D, Representative example of a parafﬁn section from an E10.5
Atrxwt/null embryo, cut in transverse orientation through the trunk, stained for Atrx. All cells in comparable sections from wild-type
embryos were Atrx positive. An intra-aortic cluster and other features are marked, with the boxed area shown at higher magniﬁcation
on the right. Scale bars are 100 mm (left) and 25 mm (right). E, Percentage of Atrx-negative cells within intra-aortic clusters in six
embryos (black diamonds) and the mean (red dot), for a total of ∼500 cells scored.
a much higher proportion of Atrx-negative cells remained
in the mice with postnatal ablation of Atrx than in those
bearing the null allele, throughout embryogenesis. This
suggested that, in general, cell selection resulting in
skewed XCI is restricted to particular stages of develop-
ment in carriers of an Atrx mutation.
Discussion
Skewed XCI Caused by Cell Selection, Not a General
Cellular Defect
It is widely assumed that, in the majority of monogenic
X-linked disorders associated with skewed XCI, the skew-
ing is a result of cells with the mutant allele on the active
chromosome being outcompeted by cells expressing the
normal allele. We have shown, using a mouse model, that
mutation of the XLMR gene Atrx does indeed lead to
skewed inactivation due to cell selection during embry-
ogenesis. The initial XCI pattern is balanced, indicating
that loss of Atrx does not cause skewing by altering the
choice of which chromosome is inactivated. Therefore,we
have demonstrated that the assumption of cell selection
is likely to be valid for cases such as ATR-X syndrome.
Carriers of ATR-X syndromemutations have skewedXCI
in multiple tissues,23 and it has been proposed that many
XLMR mutations may lead to widespread skewing due to
a general defect in cell viability or proliferation.12 How-
ever, the evidence presented here strongly suggests that
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Figure 7. Mx1Cre-mediated recombination in hematopoietic tis-
sues. A, Example of an SacI-digest Southern blot with DNA from
an Atrxﬂox/Y Mx1Cre male mouse after pI-pC–induced recombina-
tion and phenylhydrazine treatment, showing samples taken from
the tail, spleen, and bone marrow (BM). The intron 17 probe dis-
tinguishes the Atrxﬂox (ﬂox) and the recombined null alleles (D18
and D18Dneo), as described by Garrick et al.25 Recombination is
highly efﬁcient in the spleen and bone marrow but not in the tail.
B, Cytospin (stained with modiﬁed Wright’s stain) of spleen cells
from a phenylhydrazine-treated recombined Atrxﬂox/Y Mx1Cre male
mouse. An example of a polychromatic/orthochromatic erythro-
blast is indicated by a red arrow, and a proerythroblast by an orange
arrow, demonstrating that erythropoiesis can occur in the absence
of Atrx.
the defect caused by loss of Atrx only causes a selective
disadvantage at discrete stages of development. One
would predict that a general cellular defect would result
in early and/or continuous selection, and yet we have
found that processes involving multiple cell divisions,
such as stress-induced adult hematopoiesis, canoccurwith
no major selection. We suggest, therefore, that it should
not be assumed that the presence of skewed XCI through-
out the body is caused by either an event early in embry-
ogenesis or a general cellular defect. This may be the case
for some X-linked mutations, but loss of Atrx causes mul-
tiple, apparently independent selection events at different
times in different tissues.
The ATRX Mouse Model
By necessity, this work has relied on a mouse model to be
able to analyze a wide range of tissues throughout em-
bryogenesis. Therefore, certain caveats must be considered
when this data is used to understand the human disorder.
The Atrx mutation studied is a null allele, in contrast with
ATR-X syndrome mutations that, to date, all appear to be
hypomorphic (R.J.G., unpublished data). This difference
may account for the more marked phenotype of Atrxwt/null
mice compared with female carriers of ATR-X syndrome.
In addition, it is also possible that the groups of genes
affected by ATRX are not identical in human and mouse.
Therefore, the details of time and location of ATRX re-
quirement, and thus the skewing of XCI, may differ
between species. However, given the high level of con-
servation in the protein sequence, localization, and in-
teraction partners,17,26,41,42 it seems reasonable to assume
that the principles described here apply to ATR-X
syndrome.
Role of ATRX in Development
In addition to providing an example of how an X-linked
mutation leads to skewed XCI, this study also gives some
insight into the role of ATRX in development, which may
be important for understanding ATR-X syndrome. It was
initially surprising that selection against cells lacking Atrx
did not occur early in embryogenesis in most tissues, that
a notable number of these cells persisted in adult animals,
and that postnatal ablation of Atrx in males resulted in
apparently normal blood in the complete absence of this
protein. However, these data, which indicate that Atrx is
not necessary for basic cell viability or division, are con-
sistent with previous studies. Although Atrx-nullmale em-
bryos die by E9.5 during gestation, they are able to com-
plete gastrulation and are generally morphologically
normal.25 The lethal phenotype appears to be due to a
speciﬁc defect in trophoblast development. Similarly, neu-
ronal progenitors lacking Atrx exhibit increased apoptosis
only after 6 d of differentiation, not in the undifferen-
tiated state.32 Surviving null neurons express normal
markers, such as MAP2 and NF200. Collectively, this evi-
dence suggests that ATRX is most important when a cell
negotiates speciﬁc stages of differentiation or develop-
ment. Mechanistically, this could be explained by the
stages at which target genes regulated by ATRX are re-
quired. Since ATR-X syndrome has a distinct set of phe-
notypic features, these could thus result from defects at
speciﬁc stages of tissue formation, rather than from the
same problem in multiple cell types.
XCI and Understanding of X-Linked Disorders
In this mouse model, we do not see a clear correlation
between tissues that have severely skewed XCI and tissues
affected in ATR-X syndrome. Indeed, a general question
remains as to why, in a number of XLMRdisorders, skewed
XCI occurs in female carriers in tissues where there is no
apparent phenotype in affected males (such as in buccal
cells and hair roots of ATRX-mutation carriers).12,23 A pos-
sible explanation is the sensitivity of the competitive sit-
uation present in heterozygous females, in which even a
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Figure 8. Restricted, not continuous, cell selection. A and B, Atrx ablated postnatally in mice with a ﬂoxed Atrx allele by induction
of a Cre recombinase transgene controlled by the Mx1 promoter (Mx1Cre). Atrx expression was examined by immunoﬂuorescence in
bone marrow cells from wild-type (WT) adult mice, Atrxwt/ﬂox Mx1Cre females, and an Atrxﬂox/Y Mx1Cre male. A, Bone marrow, after
phenylhydrazine treatment to induce stress erythropoiesis, stained for Atrx expression (with H300 as the primary antibody and Alexa
488-conjugated as the secondary antibody) and with DAPI. Filled arrowheads indicate examples of Atrx-negative cells, and open
arrowheads indicate examples of Atrx-positive cells. B, Percentage of Atrx-negative, Atrx-positive, or ambiguous (denoted by ?) cells
in bone marrow samples, scored by staining as in panel A. Each bar represents an individual animal (∼150 cells scored per mouse),
with phenylhydrazine treatment (PHZ) or without it (PHZ). “Null” represents a recombined Atrxﬂox/Y Mx1Cre male. “BMC” shows the
percentage of Atrx-positive and -negative hematopoietic progenitor colonies obtained by methylcellulose culture of Atrxwt/null Mx1Cre
bone marrow (total of 89 bone marrow colonies). C, Parafﬁn sections of intestine and kidney from adult mice with the genotypes shown,
stained with the anti-Atrx antibody H300 as above. In wild-type mice, all intestinal villi and glomerular cells are positive for Atrx
expression (see also ﬁg. 1). “Germline” refers to mice inheriting the null Atrx allele through the maternal germline. Three Atrxﬂox/Y
Mx1Cre, four Atrxwt/ﬂox Mx1Cre, and four Atrxwt/null (germline) mice were analyzed. The percentage of Atrx-negative crypts/villi (1500
crypts per genotype) and the percentage of Atrx-negative kidney glomerular cells (1300 glomerular cells within dashed line [arrows])
were scored; the mean percentage (1 SD) is shown. The percentage of negative cells in Atrxﬂox Mx1Cre males gives an indication of
the efﬁciency of recombination after pI-pC treatment (i.e., 100% negative cells would indicate 100% recombination). Scale bars are
100 mm for intestine and 20 mm for kidney.
slight disparity between maternally and paternally ex-
pressing cells is likely to result in the dominance of one
population. By contrast, in males, a subtle defect may not
result in an observable phenotype. If not all cells are af-
fected equally, there may be competition in the male be-
tween more or less severely affected cells. A similar phe-
nomenon has been described in comparisons of the
sensitivity of detection of defects in chimeric mice and in
complete knockout mice. In chimeric animals, analogous
to heterozygous females, cell selection can be observed in
tissues that showed no apparent phenotype in complete
knockout mice, enabling the identiﬁcation of new sites of
action of genes.43–46 In addition, in the case of Atrx, the
continued survival of some null cells suggests that, once
past particular steps in development, cells lacking Atrx are
no longer at a disadvantage and appear phenotypically
normal. Therefore, in males, it may be that, if sufﬁcient
cells can overcome these developmental “hurdles,” the
tissue can develop relatively normally.
Overall, this study has demonstrated how skewed XCI
can be established over the course of development by tis-
sue-speciﬁc cell selection. This work suggests that the as-
sumption that mutations in XLMR genes such as ATRX
confer a selective disadvantage is valid but indicates that
widespread skewing is not necessarily a result of a general
defect in cell viability or proliferation. In terms of fur-
thering our understanding of X-linked disorders, altera-
tion of the XCI pattern is a sensitive indicator of gene
function. In the case of ATR-X syndrome, this study of
XCI points toward ATRX as having importance at partic-
ular stages of tissue differentiation, and this will direct
future experiments to identify target genes regulated by
ATRX thatmay be responsible for this pattern. It is possible
that establishment of how skewed XCI emerges may be a
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useful tool for gaining insight into the roles of other genes
responsible for developmental disorders.
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